Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR

Cancer Research

Volumn 61, Issue 14, 2001, Pages 5355-5361

  Luwor, Rodney B ^a   Johns, Terrance G ^a   Murone, Carmel ^a   Su Huang, H J ^c   Cavenee, Webster K ^c   Ritter, Gerd ^a   Old, Lloyd J ^a   Burgess, Antony W ^b   Scott, Andrew M ^a  

^a LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 806; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY SPECIFICITY; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; GENE AMPLIFICATION; GENE EXPRESSION; GLIOMA; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR NECROSIS; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CELL DIVISION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOTYPE; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MUTATION; NEOPLASMS, EXPERIMENTAL; PRECIPITIN TESTS; PROTEIN BINDING; RECEPTOR, EPIDERMAL GROWTH FACTOR; TRANSPLANTATION, HETEROLOGOUS; TREATMENT OUTCOME; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0035878671     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Antibody-based immunological therapies
2. Therapeutic application of anti-growth factor receptor antibodies
3. Expression of mutated epidermal growth factor receptor by non-small cell lung carcinomas
4. The class III variant of the epidermal growth factor receptor (EGFRvIII): Characterization and utilization as an immunotherapeutic target
5. Prognostic value of tumour associated antigen immunoreactivity and apoptosis in cerebral glioblastomas: An analysis of 168 cases
6. Levels of TGF-α and EGFR protein in head and neck squamous cell carcinoma and patient survival
7. Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies
8. Inhibitory effect of anti-epidermal growth factor receptor antibody on a human gastric cancer
9. Tumor growth modulation by a monoclonal antibody to the epidermal growth factor receptor: Immunologically mediated and effector cell-independent effects
10. Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies
11. A Phase I study of an anti-epidermal growth factor receptor monoclonal antibody for the treatment of malignant gliomas
12. Phase I and imaging trial of indium 11-labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma
13. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin
14. Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials
15. Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas
16. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity
17. Epidermal growth factor receptor vIII enhances tumorigenicity in human breast cancer
18. Evidence for the differential expression of a variant EGF receptor protein in human prostate cancer
19. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors
20. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas
21. Specific targeting of a mutant, activated FGF receptor found in glioblastoma using a monoclonal antibody
22. Monoclonal antibody against the fusion junction of a deletion-mutant epidermal growth factor receptor
23. A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis
24. Derivation and assay of biological effects of monoclonal antibodies to epidermal growth factor receptors
25. The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling
26. Therapeutic efficacy of anti-Lewis(y) humanized 3S193 radioimmunotherapy in a breast cancer model: Enhanced activity when combined with Taxol chemotherapy
27. Growth regulation of human renal carcinoma cells: Role of transforming growth factor α
28. Tumor epidermal growth factor receptor studies in patients with non-small-cell lung cancer or head and neck cancer treated with monoclonal antibody RG 83852
29. Intratumoral infusion of the monoclonal antibody, mAb 425, against the epidermal-growth-factor receptor in patients with advanced malignant glioma
30. Malignant astrocytomas treated with iodine-125 labeled monoclonal antibody 425 against epidermal growth factor receptor: A Phase II trial
31. Tumor-specific anti-epidermal growth factor receptor variant III monoclonal antibodies: Use of the tyramine-cellobiose radioiodination method enhances cellular retention and uptake in tumor xenografts
32. Improved targeting of an anti-epidermal growth factor receptor variant III monoclonal antibody in tumor xenografts after labeling using N-succinimidyl 5-iodo-3-pyridinecarboxylate
33. Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors
34. Epidermal growth factor receptor gene-amplified MDA-468 breast cancer cell line and its nonamplified variants
35. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts
36. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies
37. Monoclonal antibody drag conjugates in the treatment of cancer
38. A new era for radiolabeled antibodies in cancer?